



Evidence reviews – February 2023

Evidence review

Published: 8 February 2023

www.nice.org.uk

The following documents contain the evidence that was used to develop the 2023 recommendations:

- [Patient information and support](#)
- [Pharmacological interventions to reduce progression to dysplasia or cancer](#)
- [Endoscopic surveillance using white light endoscopy](#)
- [Diagnostic accuracy of endoscopic surveillance techniques](#)
- [Non-endoscopic surveillance techniques](#)
- [Frequency and duration of endoscopic surveillance](#)
- [Endoscopic and radiological staging techniques](#)
- [Endoscopic treatment \(high-grade dysplasia and stage 1 adenocarcinoma\)](#)
- [Endoscopic treatment \(low-grade dysplasia and indefinite dysplasia\)](#)
- [Endoscopic and radiological follow-up after treatment](#)
- [Oesophagectomy versus endoscopic treatment](#)
- [Non-surgical treatment for T1b oesophageal adenocarcinoma](#)
- [Anti-reflux surgery to induce remission of disease or prevent recurrence](#)
- [Anti-reflux surgery to reduce progression to dysplasia or cancer](#)

Other supporting evidence

- [Methods](#)